From research grants, to exciting discoveries and treatment breakthroughs, read the latest research news from the Melanoma Institute Australia team as we work tirelessly towards our goal of zero deaths from melanoma.
Cutaneous melanoma: a contemporary overview published in The Lancet
A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
Prof Richard Scolyer receives SMR Lifetime Achievement Award
This prestigious award from the 'Society for Melanoma Research' recognises the contribution Richard has made to global melanoma research over the course of his career.
Major advance for neoadjuvant treatment of melanoma
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
MIA researchers share learnings on global stage at ASCO23
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
Prof Richard Scolyer awarded IAP ‘Distinguished Pathologist’ Medal
Read more about why Prof Richard Scolyer AO received the IAP Distinguished Pathologist Medal and watch his inspiring acceptance speech.
Prof Richard Scolyer AO honoured with ASDP Founders’ Award
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
Expanded PBS access to immunotherapy treatment
Combined immunotherapy ipilimumab and nivolumab is now available on the PBS for all advanced melanoma patients.
A second penicillin moment for cancer treatment
In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
Clarivate announce Highly Cited Researchers 2022 list
Read more about the five MIA researchers named on the Clarivate list of Highly Cited Researchers 2022.
MIA team receives 2022 Wildfire Highly Cited Publication Award
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
MIA shares latest research breakthroughs at world’s largest melanoma conference
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Australian researchers identify link between diet, gut microbiome and response to treatment
Diets low in fibre and omega-3 fatty acids linked to poorer response to immunotherapy.
